Wednesday, November 8, 2017 | Noon–1 p.m. CT
The webinar will briefly cover the current knowledge concerning the molecular genetic classification of adult gliomas.
Devin Oglesbee, Ph.D., Director of the Biochemical and Molecular Genetics Laboratories at Mayo Clinic, provides an overview of the lysosomal storage disease panel, when it is appropriate to order this test, what actions the results allow you to take, and how this test improves upon previous approaches.
Gessi Bentz Pino, CGS, a Genetic Counselor in the Department of Laboratory Medicine and Pathology at Mayo Clinic, provides an overview of the lysosomal storage disorders screen, when it is appropriate to order this test, what actions the results allow you to take, and how this test improves upon previous approaches.
A recent Huff Post article, authored by the Mayo Clinic Center for Individualized Medicine, highlights three genetics tests to improve prenatal screening, including Mayo Medical Laboratories’ cell-free DNA prenatal screen.
Newborn screening panels (that test for a variety of conditions) are available in every state; however, test performance and response rate by each state is very different. Mayo Clinic’s Biochemical Genetics Laboratory created the Collaborative Laboratory Integrated Reports tool to mitigate the national (and international) problem of false positives and to raise the bar on test performance.
Mayo Clinic has launched a first-of-its-kind clinical test that will be used to help patients who may be at a diagnostic “dead end” with other genetic testing. The mate-pair sequencing test can identify chromosome alterations or “breakpoints” involved in chromosome rearrangements, pinpointing the precise genes involved.
Originally Presented February 24, 2017
Chromosome analysis, which was once the preferred genetic test for a wide variety of congenital abnormalities, is now one of the most frequently misordered cytogenetic tests at MML. This webinar will outline the differences in technologies and the appropriate use of each test.
The recommendations surrounding newborn screening are constantly in flux. Newly discovered treatments or emerging laboratory technologies are enabling additional recommendations for newborn screening.
Identifying the correct test for your patient is always critical. In this two-part presentation, Lea Coon, C.G.C., walks viewers through the information necessary to correctly select testing for hemophilia A or B.
In cases of sudden or unexpected death, autopsy evaluation can include a biochemical analysis to identify deaths caused by fatty acid oxidation disorders.